Researchers seek better way to track cancer drug effectiveness
NCT ID NCT03963518
Summary
This study looked at whether 'time until a patient needs new treatment or dies' is a good measure of how well immunotherapy drugs work for advanced melanoma. Researchers analyzed data from 631 patients with previously untreated advanced melanoma to see if this measurement accurately predicts overall survival. The goal was to help future cancer trials use more meaningful, patient-relevant measures of treatment success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER TREATED WITH IMMUNE-CHECKPOINT INHIBITORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Bergonié, Comprehensive Cancer Center
Bordeaux, France
Conditions
Explore the condition pages connected to this study.